Mineralys Therapeutics: Funding, Investors & Team (Oct 2026)
Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company founded by Catalys Pacific committed to developing best-in-class, novel therapy for the treatment of hypertension. The Company is driven to bring a targeted approach to the management of hypertension via the development of MLS-101. MLS-101, licensed from Mitsubishi Tanabe Pharma Corporation, is a highly selective and potent aldosterone synthase inhibitor that is being investigated for the treatment of hypertension.
Mineralys Therapeutics has raised $540M across 2 funding rounds on record, the most recent an undisclosed round of $500M announced in Jun 2026.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Mineralys Therapeutics Company Profile and Key Stats
Latest funding round on record: Jun 2026.
Mineralys Therapeutics Funding Rounds
Mineralys Therapeutics raised $40.0M in a Series A announced in Apr 2021.
5.2 years later, an undisclosed round of $500M was announced in Jun 2026.
Mineralys Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Mineralys Therapeutics Funding Compared to Other Biotechnology Startups
Mineralys Therapeutics' latest round of $500M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Mineralys Therapeutics in Biotechnology and Radnor
Companies Similar to Mineralys Therapeutics
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Datavant is a developer of a healthcare data platform dedicated to assisting in protecting, matching, and…
Mineralys Therapeutics Funding FAQs
What does Mineralys Therapeutics do?
Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company founded by Catalys Pacific committed to developing best-in-class, novel therapy for the treatment of hypertension. The Company is driven to bring a targeted approach to the management of hypertension via the development of MLS-101. MLS-101, licensed from Mitsubishi Tanabe Pharma Corporation, is a highly selective and potent aldosterone synthase inhibitor that is being investigated for the treatment of hypertension.
How much funding has Mineralys Therapeutics raised?
Mineralys Therapeutics has raised $540M across 2 rounds on record. The most recent is an undisclosed round of $500M announced in Jun 2026.
When did Mineralys Therapeutics last raise funding?
Mineralys Therapeutics' most recent funding round on record is an undisclosed round of $500M, announced in Jun 2026.
Who is the CEO of Mineralys Therapeutics?
Jon Congleton is listed as CEO at Mineralys Therapeutics.
Where is Mineralys Therapeutics headquartered?
Mineralys Therapeutics is based in Radnor, Pennsylvania, United States.
How many employees does Mineralys Therapeutics have?
Mineralys Therapeutics is in the 1-10 employee band.
How does Mineralys Therapeutics' funding compare to other Biotechnology startups?
Mineralys Therapeutics' latest round of $500M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Mineralys Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Mineralys Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.